EPIGENETIC ALTERATIONS IN GENES FROM LIQUID BIOPSIES PROVIDE INSIGHT INTO DRUG RESISTANCE IN NON-SMALL LUNG CANCER PATIENTSLongitudinal analysis of paired samples of CTCs and ctDNA shows important differences
Angle PLC Announces Insight into Drug Resistance in NSCLC pittsburghstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pittsburghstar.com Daily Mail and Mail on Sunday newspapers.
Investegate |Angle PLC Announcements | Angle PLC: Accelerated bookbuild to raise up to £20m investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy company, today announces audited preliminary results for the year ended 31 December 2020. · Full De Novo Submission made in September 2020 for US Food and Drug Administration (FDA) clearance of the Parsortix
® system for capturing and harvesting circulating tumour cells from metastatic breast cancer patients - FDA Administrative Review complete and Substantive Review in progress - FDA Additional Information Request (AIR) received and response planned for submission in May 2021
- patient enrolment completed after the year end - surgical procedures in progress and sample analysis in preparation - study expected to report headline results in Q4 2021